E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Human Immunodeficiency Virus |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the acceptability, safety and tolerability of cART intensification with cenicriviroc in PLWH with cognitive impairment,
|
|
E.2.2 | Secondary objectives of the trial |
To assess the cerebrospinal fluid (CSF) exposure of cenicriviroc in PLWH on cenicriviroc containing cART,
To assess changes in cerebral function parameters subsequent to cART intensification with cenicriviroc. Cerebral function parameters will include cognitive testing results, CSF biomarkers measured via lumbar puncture examination and neuroimaging biomarkers.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Aged 18 or over at Screening, male or female subjects
2. Documented HIV-1 infected
3. Undetectable plasma HIV RNA (<200 copies/mL) for at least 6 months
4. Demonstrated clinically significant cognitive impairment (see section 8.3)
5. On cART comprising of BHIVA guideline recommended therapies (2015 guidelines) with the exception of elvitegravir/cobicistat and rilpivirine
6. Comorbidities, if present, are stably managed for at least 6 months
7. No clinically significant recreational drug use or alcohol dependence
8. Male subjects who are heterosexually active must either:
a. Use 2 forms of highly effective barrier contraception (e.g. condom & diaphragm) during heterosexual intercourse from screening through to at least 3 months after discontinuation of study medication
b. Be truly abstinent, when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception]
9. Female subjects may be eligible to enter and participate into the study if she:
a. Is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
b. Is of child-bearing potential with a negative pregnancy test at both Screening and Day 0 and agrees to use one of the following methods of contraception to avoid pregnancy;
c. Is truly abstinent, when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception].
d. Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide);
e. Reliable highly effective contraceptives unaffected by enzyme inducers such as copper-bearing intrauterine device (Cu-IUD), Levonorgestrel-containing Intrauterine system (IUS) or progestogen-only injectable with published data showing that the expected failure rate is <1% per year;
f. Male partner sterilization confirmed prior to the female subject’s entry into the study, and this male is the sole partner for that subject;
g. Approved hormonal contraception such as the combined oral, patch or ring contraceptive, and progestogen only pill (POP) or implant must be used with an additional contraceptive precaution, such as condoms, during and for 28 days after stopping Cenicriviroc. This is because Cenicriviroc, a CYP3A4 enzyme inducer, may increase the rate at which these hormonal contraceptives are metabolised;
h. Any other method with published data showing that the expected failure rate is <1% per year
Any contraception method must be used consistently, in accordance with the approved product label and for at least 3 months after discontinuation of study medication.
|
|
E.4 | Principal exclusion criteria |
1. Current major depression (score of 15 or more on PHQ-9 score at study screening)
2. Chronic neurological diseases (e.g. epilepsy and stroke; at the discretion of the investigator)
3. History of severe head injury (with loss of consciousness for >30 minutes)
4. Cerebral AIDS defining infections
5. Current intravenous drug use (past six months)
6. Severe psychiatric disease (at the discretion of the investigator)
7. Contra-indication for MRI scan (e.g. claustrophobia, metal in body, physically unable to lie flat)
8. Contraindications to lumbar-puncture examination (at the discretion of the investigator)
9. Current or previous use of CCR5 inhibitors (maraviroc, cenicriviroc or others)
10. Disallowed medication which may interact with cenicriviroc (section 11.2)
11. Chronic liver disease
12. Breastfeeding
13. Laboratory investigations at screening out with the follow cut-offs:
• Haemoglobin < 8.5 g/dL;
• Absolute neutrophil count < 1000;
• Platelet count < 100,000;
• ALT or AST> 2.5 X upper limit of normal ;
• estimated creatinine clearance < 60 mL/min (Cockcroft and Gault 1979)
14. In the opinion of the investigator unable to comply with study procedures
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
3 primary outcomes:
- acceptability (measured via patient questionnaires)
- pharmacokinetic results (measured via CSF and plasma PK)
- cerebral function parameters (cognitive testing, neuro imaging modalities)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 31 |